Glaukos Corporation
GKOS
주식 순위
#2087
Glaukos Corporation operates as an ophthalmic medical technology and... Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
주가
$166.79
마지막 동기화: 2026-10-19
시가총액
$9.84B
변동 (1일)
1.44%
변동 (1년)
109.88%
국가
US
거래 Glaukos Corporation (GKOS)
카테고리
Healthcare
Glaukos Corporation (GKOS)의 P/B 비율
October 2026 기준 P/B 비율 TTM: 14.37
Glaukos Corporation의 최신 재무 보고서와 주가에 따르면 현재 P/B 비율(TTM)은 14.37입니다. 2023년 말 기준 P/B 비율은 8.34였습니다.
Glaukos Corporation의 P/B 비율 기록 (2012 ~ 2026)
매년 말 P/B 비율
| 연도 | P/B 비율 | 변화 |
|---|---|---|
| 2026 (TTM) | 14.37 | 39.39% |
| 2024 | 10.31 | 23.71% |
| 2023 | 8.34 | 113.23% |
| 2022 | 3.91 | 11.28% |
| 2021 | 3.51 | -29.97% |
| 2020 | 5.02 | 66.02% |
| 2019 | 3.02 | -73.28% |
| 2018 | 11.31 | 77.22% |
| 2017 | 6.38 | -33.74% |
| 2016 | 9.63 | 112.49% |
| 2015 | 4.53 | -188.26% |
| 2014 | -5.13 | -6.61% |
| 2013 | -5.50 | -74.41% |
| 2012 | -21.48 | 0.00% |
유사 기업 또는 경쟁사의 P/B 비율
| 회사 | P/B 비율 | P/B 비율 차이 | 국가 |
|---|---|---|---|
| 3.5116 | -75.56% |
US
|
|
| 2.0146 | -85.98% |
IE
|
|
| 4.5025 | -68.67% |
US
|
|
| 2.5486 | -82.27% |
US
|
|
| - | - |
DE
|
